Evoke Pharma's yearly report showed better-than-expected revenues and losses per share. The analyst predicts a 56% revenue increase in 2025, but also a 69% rise in losses. The consensus price target dropped by 79%, indicating concern about the company's future prospects.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing